SCHEMBL10069079

SCHEMBL10069079

COc1cc(OC)c(OC)cc1/C=C/c1cccc(/C=C/c2cc(OC)c(OC)cc2OC)[n+]1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 10/20 0.53
CYP1B1 Q16678 10/20 0.53
CYP1A2 P05177 9/20 0.53
HMGCR P04035 1/20 0.52
CYP3A4 P08684 1/20 0.52
NFE2L2 Q16236 2/20 0.46
ABCG2 Q9UNQ0 1/20 0.45
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 2/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42
ACHE P22303 2/20 0.41
BCHE P06276 1/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13127031 0.85 KDM1A (0.47) CYP1A1CYP1B1CYP1A2HMGCRCYP3A4
SCHEMBL10069081 0.82 CYP1A2 (0.69) CYP1A1CYP1B1CYP1A2CYP3A4NFE2L2
SCHEMBL13127029 0.79 MEN1 (0.37) CYP1A1CYP1B1CYP1A2NFE2L2ALDH1A1
SCHEMBL10069210 0.79 CYP1A1 (0.45) CYP1A1CYP1B1CYP1A2HMGCRCYP3A4
SCHEMBL13126961 0.79 MEN1 (0.54) CYP1A1CYP1B1CYP1A2CYP3A4NFE2L2
SCHEMBL10069720 0.78 MEN1 (0.66) CYP1A1CYP1B1CYP1A2NFE2L2ABCG2
SCHEMBL10069726 0.77 CYP1A1 (0.44) CYP1A1CYP1B1CYP1A2HMGCRCYP3A4
SCHEMBL10069719 0.77 NFE2L2 (0.39) CYP1A1CYP1B1CYP1A2NFE2L2MEN1
SCHEMBL13126939 0.77 CYP1A1 (0.54) CYP1A1CYP1B1CYP1A2NFE2L2ABCG2
SCHEMBL13126949 0.76 CYP1A1 (0.43) CYP1A1CYP1B1CYP1A2HMGCRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124626-B2 Methods of treating inflammations and infections with pyridinium salts MYCOSOL, INC. (US) 2012-02-28 US disclosed
US-7820696-B2 Compounds and methods for controlling fungi, bacteria and insects MYCOSOL, INC. (US) 2010-10-26 US disclosed
US-20100267716-A1 METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS KLEIN RICHARD B 2010-10-21 US disclosed
US-20070213299-A1 COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS MYCOSOL, INC. 2007-09-13 US disclosed
US-7220761-B2 Compounds and methods for controlling fungi, bacteria and insects MYCOSOL, INC. (US) 2007-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213299-A1 COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS BLVRB, PNPO, PLPBP CYP1A1 1805/4885CYP1B1 1069/4885CYP1A2 1498/4885
US-20100267716-A1 METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS PNPO, PLPBP, TPMT CYP1A1 1400/4885CYP1B1 1410/4885CYP1A2 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.